Evaluation of a Clinical Decision Support System for Dyslipidemia Treatment (HTE-DLPR) by QoE questionnaire by Zamora, Alberto et al.
Evaluation of a Clinical Decision Support System 
for Dyslipidemia Treatment (HTE-DLPR) by QoE 
Questionnaire 
Alberto Zamora 1, 2, Carme Carrion 2, 3, Marta Aymerich 2, 3, 
Xavier Castells 2, Lidia Blanco 2,  Anabel Martin-Urda 2, Guillen 
Paluzie 1, Dolors Capella 2, Roberto Elosua 5, In Representation 
of Valida Group.
1 Department of Internal Medicine, Hospital of Blanes, Blanes, Girona, Spain
2 Group of TransLab Research, Department of Medical Sciences, University of 
Girona, Catalonia, Spain
3 Open University of Catalonia, Barcelona, Spain
4 Department of Internal Medicine, Integrated Health Services of Lower Emporda 
Hospital Palamos, Girona, Spain
5 Group of Cardiovascular Epidemiology and Genetics, Hospital Del Mar Medical 
Research Institute, Barcelona, Spain 
* Corresponding author: Alberto Zamora, Department of Internal Medicine, Hos-
pital of Blanes, Blanes, Girona, Spain. Tel: +34 677852228, E-mail: azamorac.
zamora@gmail.com 
Abstract
Introduction: Clinical decision support systems (CDSS) are computer systems 
designed to assist clinicians with patient-related decision making, such as diagnosis and 
treatment. CDSS have shown to improve both patient outcomes and cost of care.
Methods: A multi-center observational prospective study was conducted. Ten physicians 
agreed to participate. Seventy-seven patients with high or very high cardiovascular risk 
were included. After using CDSS for dyslipidemia (HTE-DLPR) for a 3 months period, 
participants were asked to evaluate their experience with HTE-DLPR using a quality of 
experience questionnaire (QoE) tool for mHealth applications.
Results: Total score on the QoE was 3.89 out of 5. The highest scores were received 
for precision, ease of use and content quality. The lowest scores were given to security, 
appearance and performance. Physicians were in strong agreement with the 1st HTE-
DLPR recommendation in 86.1% and the system’s use was described as comfortable 
in 85% of cases. Users positively evaluated the development of a new version of HTE-
DLPR in the future receiving a total score of 4.25 out of 5.
Conclusions: A CDSS for dyslipidemia (HTE-DLP) has been positively evaluated by 
physicians using QoE questionnaire. 
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Despite high serum cholesterol levels have been linked to ma-
jor cardiovascular disease less than 20% of patients with very 
high cardiovascular risk have optimal lipid control [1]. The 
Reality Group showed that in Spain only 12.9% of patients 
attained the LDL-C goal on their initial lipid-lowering drugs 
and an additional 13.4% achieved the goal after a change of 
treatment [2]. On the other hand, 30% times, statins are 
prescribed with other drugs with potential interactions and 
9% times, the prescribed treatments are non-recommended 
[3]. In a US-based internet survey among current and former 
statin users, 25% and 60% of the responders reported statin 
related side effects [4]. E-healths tools can be a good and safe 
instrument to increase significantly the number of high risk 
patients on goal of LDL-C [5].
Considering the latest study by Institute for Healthcare In-
formatics (IMS), more than 165.000 apps of health and 
medicine are offered including all the stores from different 
platforms. It is important to note that more than 50% of the 
available apps received less than 500 downloads and only 
five of them comprise 15% of all those in the health category. 
The IMS attributed this situation to different causes, which 
include: poor quality in many of them, the lack of guidance 
on the usefulness of the app and a low level of support from 
health professionals [6]. Furthermore, a meta-analysis con-
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cluded that only around 60% of these new technological 
processes actually succeed in improving clinical practice [7]. 
On the other hand, this is an area of increasing concern for 
healthcare authorities, given that these heath applications 
are not always rigorously evaluated [8]. Users and Physicians 
should know the quality of the mHealth applications that 
they are using or prescribing. mHealth should be rigorously 
evaluated to ensure that they provide evidence-based effec-
tiveness, safety and efficacy. These evaluation studies should 
be robust, standardized and their results should be reported 
in line with verified standards [9]. Certification schemes for 
mHealth applications should be developed to serve as reli-
able indicators for healthcare professionals and citizens [5]. 
Direct participation of users in the health technology assess-
ment process allows them to be part of the decision-making 
process [10]. Some tools used to evaluate mHealth appli-
cations from users view such as the quality of experience 
questionnaire (QoE) [11] or the Mobile App Rating Scale 
(MARS) [12] have been suggested. 
Patient data management systems (PDMS) integrated with 
a clinical decision support system (CDSS) can improve out-
comes in chronicles diseases as hypercholesterolemia [13]. 
HTE-DLPR is the first CDSS and PDMS system developed 
to monitor dyslipidemia treatment in Spain and the first to 
be validated in clinical practice in Europe [14]. HTE-DLPR 
performs a sequence of clinical decisions as expert lipidolo-
gyst including all statins and ezetimibe and creates specific 
recommendations for each patient using efficiency, safety 
and cost criteria. A multi-center observational prospective 
study has revealed that the number of patients at very high 
cardiovascular risk, reaching the treatment goal defined by 
the European Guidelines for the Management of Dyslipid-
emia 2011 [15] (LDL-C < 70 mg/dL.), increases 4.4 times 
when expert clinicians in the lipidology field use HTE-DL-
PR [14]. So, This study demonstrated that in the “real-clin-
ic-world” expert physicians in the cardiovascular field can 
improve cholesterol management by using a specific CDSS. 
The cost of reducing 1 mg/dL of LDL-C was less in the in-
tervention group than in control group (0.89 EUR/day vs 
1.10 EUR/day [14]. Physicians expressed good agreement 
with the 1st HTE-DLP recommendation in 86.1% of cases 
and use was described as ease in 85% of cases. It rating yet 
that using HTE-DLPR throughout Spain in 2020 may poten-
tially lead to a decrease in fatal and nonfatal coronary events 
in patients between the 35 to 74 years by 5.4% and 7.4% in 
men, between 1.8% and 2.0% in women. This corresponds to 
a decrease in healthcare costs derived from coronary disease 
between 4.7% and 6.4% [16]. It showed too that using a spe-
cific CDSS can represent a cost-effective intervention. Before 
disseminating HTE-DLPR in clinical practice it is important 
to know clinicians’ opinion about its usability.
The main goal of this study is to evaluate the quality of 
HTE-DLPR using a QoE tool for mHealth applications.
METHODS
Participants
Ten physicians (3 cardiologist, 4 lipidologist and 3 family 
doctors with an average age of 42 years) from three different 
hospitals and two primary healthcare centers in Catalonia 
(Spain) were invited to participate in a validation study of 
HTE-DLPR in a real clinic environment. It was performed 
a cluster-randomized trial comparing standard prescriptions 
with HTE-DLPR assistance. Included patients were ran-
domly distributed into the intervention or control group by 
a computer program. HTE-DLPR assistance was blocked 
automatically if a patient was assigned to the control group. 
Each clinician was invited to include a maximum of 8 pa-
tients in the study to avoid bias of learning by repeated use of 
HTE-DLPR. Selection criteria for participants were to have 
clinical experienced in the management of patients with high 
vascular risk and to be highly motivated to use new technolo-
gies. It included 77 patients having established cardiovascular 
disease or a 10-year risk of developing cardiovascular disease 
based on a low SCORE risk >5%. After using HTE-DLPR 
for a 3-month period, clinicians were asked to assess anony-
mously its usability using QoE tool for mHealth applications. 
Also, physicians were also consulted regarding their degree 
of acceptance of the HTE-DLPR’s first recommendation and 
their opinion about its ease-of-use. The study protocol was 
approved by a local ethics committee. All patients were asked 
about their voluntary entry into the study after signing the 
informed consent.
HTE-DLP Running
HTE-DLPR is a CDSS that mimics the clinical decision mak-
ing to be performed when an expert lipidologist prescribing 
lipid-lowering treatment. HTE-DLPR was written in Java us-
ing Open Source tools (Open JDK, Netbeans, iText, POI). 
At this prototype stage it runs as a standalone desktop ap-
plication. Its function is to provide a recommendation the 
best lipid-lowering therapy with criteria of effectiveness, 
safety and cost-effectiveness for a particular patient based on 
a lipid goals and taking into account clinical situation. The 
recommendation is a list of treatments that are effective (in 
the sense to achieve the objective) and compatible with the 
patient (not contraindicated). Moreover, this list is sorted 
by a number of criteria of safety, cost and efficiency so that 
the treatments considered “best” are presented before those 
considered “less good”. The program works from a case that 
the user is defined by the following parameters: LDL-C ini-
tial, risk profile (with corresponding LDL-C target), sex, 
HDL-C (optionally), situations relevant and concomitant 
treatments of patient. Firstly, HTE-DLPR applies selection 
criteria to discard statins which are contraindicated if renal or 
liver dysfunction or severe drug interactions exist. Secondly, 
treatments are selected with the necessary power to reduce 
LDL-C. LDL-C/HDL-C is a secondary target applicable 
only when user-specified. Following this, HTE-DLPR ap-
plies order criteria to compare all selected treatment options 
in pairs. Drug interactions and market prices are parameter-
ized, prioritizing first safer lipid-lowering therapy and then 
cheaper products. When HTE-DLPR detects a difference, the 
comparison process ends and the program orders all selected 
treatments from best to worst. Clinicians can choose any rec-
ommendations of treatment made by HTE-DLPR, regard-
less of place of order in the ranking assigned for the program. 
All of these processes are done with a single click on-screen 
in less than one second. HTE-DLPR allows on-line updating. 
Patients data are anonymized. Updates of HTE-DLPR were 
sent by e-mail to the platform administrator. It is based on 
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European Guidelines for the Management of Dyslipidemia 
2011 [15] and its scientific content has been verified by two 
experts’ lipidologist using peer-review method. Equally, two 
independent computer engineers have tested the software 
and hardware and certified that HTE-DLPR met the rules on 
confidentiality and data protection of patients. 
QoE Questionnaire
QoE is a feasible tool for measuring the usability of techno-
logical applications from user perspective. It´s a tool devel-
oped from the Department of Signal Theory and Communi-
cations, and Telematics Engineering, University of Valladolid, 
Spain, to assess the Quality of Experience of mobile mHealth 
applications in order to improve the quality of the existing 
apps and the ones to be released. This tool has been positively 
evaluated using a sample of health applications. QoE consists 
in 18 questions with a Likert scale of five possible response 
options. Thus, all questions may be scored from 1 to 5 with 
the following meanings: 1: Strongly disagree; 2: Disagree; 3: 
Neither agree nor disagree; 4: Agree, and 5: Strongly agree. 
The following application fields are measured [17] (Table 1): 
a) Accuracy (question 1): quantifies the accuracy of the ap-
plication’s calculations
b)  Ease of use (questions 2-4): determines the difficulty of 
managing the application by the user
c) Content quality (questions 5-10): asses user perception of 
the quality of the application content
d) Ease of Learning (question 11) : rates specifies the ease of 
learning how to use the application 
e) Availability (question 12): appraises guarantee of access to 
the information at any time
f) Security (questions 13-14): titrates data security level pro-
vided by the application
g) Appearance (questions 15-16): evaluate the product’s ex-
ternal interface
h) Performance (questions 17-18): measure up errors, unex-
pected performance halts, application response time
Table 1: Specific Assessment of HTE-DLP by the QoE Questionnaire for mHealth Applications a, b
Questions  Results
Precision 4.5 ± 0.52
Do you think the calculations made by this application are correct? 4.5 ± 0.5
Ease of Use 4.16 ± 0.38
Do you think that the traditional method used thus far is more difficult or does not exist? 4.16 ± 0.38
Did you find what you needed? 4.33 ± 0.65
Is this application useful for monitoring the disease? 4 ± 0.73
Content Quality 4.08 ± 0.36
Does it provide the functions that you expected? 4.66 ± 0.49
Do you think the data is reliable? 4.42 ± 0.51
Does the application receive regular updates? 4.25 ± 0.75
Is it possible to send information on your status to your doctor? 4.08 ± 0.66
Is your quality of life better thanks to the use of this application? 4 ± 0.73
Can you identify with the health problems in this application? 3.91 ± 1.08
Learning 3.91 ± 0.51
Do you think that the time for learning to use the application is appropriate? 3.83 ± 0.83
Availability 3.91 ± 1.16
Are you guaranteed access to the application and its data at any time? 3.91 ± 1.16
Security 3.75 ± 1.05
Do you think that this application has adequate security methods to protect the data that is introduced? 3.75 ± 1.05
Do you think that the data obtained with this application is sufficiently protected? 3.75 ± 1.05
Appearance 3,41 ± 0.92
Do you find the appearance of this application to be adequate? 3.83 ± 0.83
Wouldn´t you change or add anything to this application 3 ± 1.20
Performance 3.41 ± 0.92
Do you think its performance couldn´t be more optimized? 3.6 ± 1.15
Haven`t you encountered any errors or problems when using the application? 2.5 ± 1.24
a Results are presented as Mean ± Standard Deviation.
b Maximum score is 5.
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Each category is given a separate scoring based on a prepa-
ratory qualitative evaluation of the aforementioned aspects. 
Furthermore, QoE it is complemented by four questions 
regarding user views on the future possibilities of mHealth 
applications. Total completion time for the 22 questions was 
in 1-2 minutes. A total score is obtained by averaging each 
individual item. A total score < 3 was considered a negative 
assessment; a score between 3 and 3.5 was considered ac-
ceptable, a score between 3.5 and 4 was considered a good 
evaluation and score above 4 was considered an excellent 
evaluation.
Physicians were also consulted regarding their degree of ac-
ceptance of the HTE-DLPR’s first recommendation and their 
opinion about its ease-of-use with the question “How would 
you rate the ease-of-use of HTA-DLPR“.
Data were analyzed using IBM-SPSS Statistics v.21.0.0 de-
scriptive statistics were used for comparison of the groups. 
Inter-group differences for continuous variables were evalu-
ated using the t-test and Manne Whitney test. A univariate 
analysis with categorical variables was performed using the 
chi-square test and Fisher’s exact test. All statistical tests were 
two-sided and a value of <0.05 was considered significant. 
The study was designed to have 95% power to detect at least 
a 40% difference between the intervention and the control 
group [14]. Results are expressed in mean and standard de-
viation (SD).
RESULTS
Overall, the total score on the QoE was 3.89 (0.48) on a 
maximum score of 5 (Table 1). All categories received 
scores that were above 3. The highest scores obtained were: 
precision, ease of use and content quality, all of them above 
4.0. On the other hand, the lowest ratings were given to se-
curity, appearance and performance. Individually, the only 
question that scored a lower score than 3 (2.5 SD 1.24) was 
“Did you encounter any errors or problems when using the 
application? (Performance). An agreement of 86, 1% of the 
first HTE-DLPR recommendation was achieved among 
clinicians and it was defined as being comfortable by 85% 
of the participants. Users positively evaluated the potential 
development of a new version of HTE-DLPR in the future, 
especially in the app format, giving it a total score of 4.25 
(SD 0.46) (Table 2).
Regarding clinical results, greater proportion of high car-
diovascular risk patients reached the LDL-C < 70 mg/mL 
[55.0% vs 12.5%, p 0.003; OR: 3.26 IC (1.16-9.15)]. 75% of 
patients achieved LDL-C goal < 100 mg/dL in HTE-DLPR 
users vs 45% in control group (OR 1.70 IC 1.002-2.9). Mean 
decreased LDL-C was greater in intervention vs control 
group (LDL-C 63.3 SD 51 and LDL-C 33.8 SD 47 respec-
tively). “High potency statins” and combined therapy were 
used more frequently in the intervention group than the con-
trol group (P = 0.001).
DISCUSSION
A specific CDSS (HTE-DLPR) not only improve the man-
agement of dyslipidemia in high and very high cardiovascular 
risk patients and but also has been positively assessed by ex-
pert clinicians in hypolipemiant drug prescription. 
As far as we know, this is the first study in which a CDSS for 
prescribing lipid-lowering therapy has been analyzed with a 
standardized tool for mHealth applications. We believe that 
global positive evaluation of HTE-DLPR is due to the signif-
icant participation of vascular risk experts in the design of 
its hardware and software [14]. Therefore, clinicians have en-
sured that HTE-DLPR is faithful to top scientific evidence 
and the recommendations of the European Society of Arte-
riosclerosis [15]. A recent survey showed that only in 67% 
of medical APPs expert involvement and in 87% of cases ad-
herence to medical evidence was found [18]. It is important 
to develop peer-review systems of medical Apps or CDSS 
assessing expert medical involvement and adherence of con-
tent to current guidelines as Health Apps Library, developed 
by the National Health Service in the United Kingdom [19]. 
Furthermore, the scores obtained by HTE-DLPR in the se-
curity area of QoE reflect the extreme importance that users 
give to safety of storing clinical data, in order to ensure pa-
tient confidentiality [20]. It may be the case that HTE-DL-
PR administrator update requirement resulted in a decreased 
user confidence regarding its security. However, updates were 
carried anonymously maintaining patient´s data privacy and 
HTE-DLPR does not store data that can identify a particular 
patient but these acts were not reflected in the instructions 
for users of HTE-DLPR. On the other hand, the fact that the 
first prototype of HTE-DLPR is a standalone desktop appli-
cation which requires prior installation to use and that it lacks 
automatic data capture have been major factors in the lower 
assessment of appearance and performance. Both factors are 
critical factors that can act as limiting barriers in its dissemi-
nation in clinical practice [21].
Using QoE tool for mHealth applications may provide ma-
jor assessment advantages in terms of providing the neces-
sary feedback to users on the detection of potential areas of 
improvement, the ability to quantitatively assess a mHealth 
application and to thereby compare it with other similar ap-
plications or future versions [17]. Based on user feedback, 
Table 2: QoE Measure for Future HTE-DLP Applications a, b
Score
Would you use the app if developed? 4.4 ± 0.66
Would this future application help in treating diseases? 4.33 ± 0.49
Do you think that in the future it may be useful to society? 4.2 ± 0.62
Do you think it would improve the user’s quality of life? 4 ± 0.85
Final Score 4.25 ± 0.46
a Results are presented as Mean ± Standard Deviation.
b Maximum score is 5.
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researchers are working on a second version of HTE-DLPR 
before extending its use to clinical practice that will incorpo-
rate web oriented-design with automatic data collection from 
electronic records and databases, latest generation warning 
systems, informative videos explaining its use and additional 
data protection specification. Another novelty is the ability 
to interact with the patient: recording if there is any prob-
lem or undesirable effect with medication to avoid it in fu-
ture prescriptions, detecting if not withdraw the medication 
prescribed of the pharmacy and facilitating communication 
with patient´s associations or platforms. A mobile medical 
application version of HTE-DLPR with specific module for 
Familial Hypercholesterolemia is anticipated.
However, user scales assessments must be supplemented by 
an analysis of the quality of the medical information prior to 
the introduction mHealth in daily clinical practice. The es-
sential criteria governing the quality benchmarking of online 
medical/health-related information resources would be: a) 
provide authorship information, including detailed infor-
mation about authors’ affiliations and credentials and about 
any medical professional involvement in content preparation 
b) list all references or sources of content c) fully disclose of 
any sponsorship or other commercial funding arrangements, 
and any potential conflicts of interest, d) ensure a balanced, 
non-biased coverage of facts and information currency 
(up-to-datedness) [22]. All these items are included in the 
presentation page of HTE-DLPR. These factors should be 
routinely considered by mHealth developers and publishers. 
Examples of medical and health apps independent certifi-
cation of scientific quality are Happtique Health App Cer-
tification [23] and validation process of “Distinctive App-
Healthy” carried out by the Agency for Health Quality of 
Andalusia, Spain [24]. Developers of HTE-DLPR research-
ers will process its certification as “healthy APP/CDSS” by 
relevant Public Health Agencies or Scientific Societies as a 
mark of quality.
Future research is necessary in order to evaluate the mHealth 
prior its dissemination in clinical practice [22]. It is import-
ant to find a balance between the necessary development of 
mHealth, which should be characterized as being disruptive, 
innovative and quick and the imperative need to validate that 
their content is based on the best clinical evidence and that 
their use is safe and useful in the clinical setting as new drugs 
or medical device is required, classically highly regulated and 
a slow adopter [22]. Independent, public and dynamic eval-
uation processes based on different validated tools includ-
ing feedback from users and patients are necessary [24]. A 
multi-disciplinary assessment process is required to ensure 
interoperability and confidentiality of clinical data, to deter-
mine the superiority of the intervention with respect to daily 
clinical practice [25], to ensure patient safety [26], to analyze 
implementation cost, impact on healthcare costs and innova-
tion value [27] and to evaluate patient´s quality of life. We 
suggest a progressive process of verification of scientific con-
tent and technical standards (phase I), validation in a simu-
lated environment [28] or/and real clinical daily (phase II), 
evaluation from users and patients (phase III), certification 
and on-going monitoring with periodic re-certification of 
mHealth applications before and after their introduction in 
daily clinical practices (phase IV) [29] (Table 3). Ideally, pri-
or to release and use in clinical practice a mHealth should be 
required mandatorily to overcome at least Phase I, and Phase 
II if its use can have health risks from users. This first assess-
ment should be discriminating, with pass or fail assessment. 
Phases III - IV could be an optional quality assessment, only 
mandatory in the case of the medical device. Phases III and 
IV also serve to compare with each other different mHealth. 
Currently, most of the mHealth applications used or pre-
scribed in daily clinical practices have only received technical 
verification (phase I-A) or clinical validation based on a small 
group of patients (phase IIA) [30]. Following this proposed 
scheme, HTE-DLPR would pass the stage III-B.
Table 3: Proposed Steps for the Clinical Implementation of Health Technologies
Definition Description Executant
Verification
Verification of  technological and clinical concepts
 Definition:
 A- Correct operation of hardware and software, standards of interoperability and safety
in data handling








 A- Clinical studies on small group of patients led by clinical experts in simulated or real
clinical environments
 B- Clinical studies in a large group of patients conducted by healthcare worker expert
and non-expert in real clinical practice
 Definition:
 Measuring the effectiveness (A), safety (B) and efficiency (B) compared to standard





A. Evaluation by public and “standard platform”  with different tools
B. Analysis of implementation cost and impact on healthcare costs.
 Definition:
 A-Evaluation by different quantitative and qualitative tools including user feedback







 A-Certification by an independent accredited agency or societies that it meets technical
 and scientific standards.
 B-Monitoring and surveillance with periodic certifications post-implementation in
clinical practice
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This study has several limitations. First, as pilot study con-
tains limited data of patients and participants and it has a 
short follow-up period. Furthermore, study participants were 
the same physicians that participated in the clinical validation 
study and this may have led to the overvaluation of certain 
aspects. On the other hand, participants that they are expert 
clinicians in management of dyslipidemia, feeling that they 
are being compared with the HTE-DLPR, may in fact under-
estimate its assessment. Another limitation of this study, it 
was not measured patient opinion. In future, it would be im-
portant to assess the effects on lipid control after incorporat-
ing the improvements proposed by users. Strengths must also 
be highlighted. It is notable the positive correlation between 
subjective assessment by users and the high score by QoE.
CONFLICTS OF INTEREST
This study concludes that HTE-DLPR has proved to be a 
satisfactory CDSS to management of dyslipidemia in high 
risk patients and also get a satisfactory assessment by clini-
cians using QoE tool for mHealths. Users have detected some 
points to be incorporated in the continuous and necessary 
process of quality improvement. QoE questionnaire can be 
a useful quantitative tool to comparing similar mHealths and 
can help to incorporate feed-back from users in the process of 
improving quality in future versions.
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